<DOC>
	<DOCNO>NCT00109031</DOCNO>
	<brief_summary>To evaluate whether palifermin ( rHuKGF ) administer single dose non-inferior 3 consecutive dos palifermin reduce incidence severe oral mucositis ( World Health Organization [ WHO ] grade 3 4 ) .</brief_summary>
	<brief_title>Palifermin Reduction Oral Mucositis Single-dose Evaluation ( PROMISE )</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Written inform consent Subjects : nonHodgkin 's lymphoma , Hodgkin 's disease , acute myelogenous leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , chronic lymphocytic leukemia , multiple myeloma Minimum 1.5 x 10^6 CD34+ cells/kg cryopreserved transplanted . Cancer specify inclusion criterion ( except : adequately treat basal cell carcinoma skin ) Prior bone marrow peripheral blood stem cell transplantation Negatively select ( purge ) stem cell product Current active infection oral mucositis Congestive heart failure define New York Heart Association class III IV . History current diagnosis pancreatitis Inadequate renal function ( serum creatinine great 1.5x upper limit normal per institutional guideline ) Inadequate liver function ( direct bilirubin great 1.5x upper limit normal , aspartate aminotransferase ( AST ) great 3x upper limit normal and/or alanine aminotransferase ( ALT ) great 3x upper limit normal per institutional guideline ) Inadequate pulmonary function measure correct diffusion capacity carbon monoxide ( DLCO ) less 50 % predict . Subject currently enrol yet complete least 30 day since end investigational device drug trial ( ) , subject receive investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Oncology</keyword>
</DOC>